A Case of Pneumocystis jirovecii Pneumonia under Belatacept and Everolimus: Benefit-Risk Balance between Renal Allograft Function and Infection

A Case of Pneumocystis jirovecii Pneumonia under Belatacept and Everolimus: Benefit-Risk Balance between Renal Allograft Function and Infection

Pneumocystis jirovecii pneumonia is an opportunistic disease usually prevented by trimethoprim-sulfamethoxazole. A 49-year-old HLA-sensitized male with successful late conversion from tacrolimus-based to belatacept-based immunosuppression developed P. jirovecii pneumonia for which he presented sever...

Full description

Bibliographic Details
Main Authors: Quentin Perrier, Antoine Portais, Florian Terrec, Yann Cerba, Thierry Romanet, Paolo Malvezzi, Pierrick Bedouch, Lionel Rostaing
Format: Article
Language:English
Published: Karger Publishers 2021-01-01
Series:Case Reports in Nephrology and Dialysis
Subjects:
pneumocystis
belatacept
antibiotic prophylaxis
iatrogenic
anti-rejection therapy
Online Access:https://www.karger.com/Article/FullText/510842

Internet

https://www.karger.com/Article/FullText/510842

Similar Items